Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Go back to Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM| (NASDAQ: NTRA) | Delayed: 391.16 -22.22 (5.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $413.38 | 52 Week High | $13.80 | |||
| Open | $408.47 | 52 Week Low | $6.52 | |||
| Day High | $416.00 | P/E | N/A | |||
| Day Low | $383.76 | EPS | $0.00 | |||
| Volume | 971,150 | |||||



